At the news
? NEUTRALIMPACT 3/10 PTAB-TRIAL filed Nov 9, 2026 at 19:00 ET
The PTAB granted institution of post-grant review (PGR2026-00061) on Neurocrine's petition challenging claims of Spruce Biosciences' patent covering methods for treating testicular and ovarian adrenal rest tumors. This is an interlocutory ruling that opens a trial; no claims have been cancelled yet.
- PTAB instituted PGR2026-00061 on November 10, 2026
- Patent U.S. 12576084 covers methods for treating testicular and ovarian adrenal rest tumors
- Neurocrine Biosciences is the petitioner; Spruce Biosciences is the patent owner
- Institution granted means the Board found it more likely than not that at least one challenged claim is unpatentable
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access